| http://www.w3.org/ns/prov#value | - Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.Image with caption: Data from Omeros' Phase 3 Clinical Program (Studies ILR003 and ILR004): Effect of OMS302 vs Control on Miosis.
|
